Drug intelligence / Profile preview

EA-1

Development stage: Unknown
Lead developer: Endo Axiom
Modality: Nanoparticles → Drug Delivery Systems, Peptides
Administration: Oral

Overview

EA-1 is an oral insulin therapeutic being developed by Endo Axiom for the treatment of Type 1 diabetes. It utilizes a proprietary silver-sulfide quantum dot (QD) oral delivery platform designed to facilitate the delivery of peptide biologics through the gastrointestinal tract. The platform is engineered for liver-targeted delivery, mimicking the natural physiological pathway of endogenous insulin secretion into the portal vein. This targeted approach aims to improve glycemic control and reduce the risk of peripheral hyperinsulinemia and hypoglycemia associated with traditional subcutaneous insulin injections. As of 2024, the program has received Human Research Ethics Committee (HREC) approval for Phase 1 clinical trials.

Other names: Oral insulin

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on EA-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EA-1.

Explore the full profile